Podcasts

Episode 31 | NSCLC and KRAS Mutations

Thoracic Oncology Group of Australasia podcast, hosted by: Associate Professor Chee Lee joined by Dr Tristan Barnes and Dr Alex Davis.

NSCLC and KRAS Mutations

In this TOGA Podcast, Australian medical oncologist, Associate Professor Chee Lee, St George Hospital, Kogarah, is joined by medical oncologist Dr Tristan Barnes, Royal North Shore Hospital, Sydney, and Dr Alex Davis, PhD candidate and medical oncologist at Chris O’Brien Lifehouse, Sydney. They discuss treatment of patients with non-small cell lung cancer with KRAS mutations, the role of co-mutations, and biomarkers that are negative predictors of response.

Furthermore, the speakers give an update on current clinical research and approval status of KRAS inhibitors as well as the clinical need for the availability of KRAS inhibitors in Australia.

Play Episode 31 | NSCLC and KRAS Mutations

More Podcasts

Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC
Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.
A/Prof Rachel Wong is joined by Dr Patrick Hosking, Dr Mal Itchins, and Dr Sagun Parakh discuss the diagnostic markers when identifying LC-NEC.
We dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining
This episode is hosted by: A/Prof Steven Kao, Prof Wendy Cooper, and Prof Ben Solomon
This episode is hosted by: Dr Pei Ni Ding, Dr Samantha Bowyer, and Mr Naveed Alam.